Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · Real-Time Price · USD

4.000

-0.080 (-1.96%)

At close: Sep 2, 2025, 4:00 PM

4.100

+0.100 (2.50%)

After-hours: Sep 2, 2025, 5:33 PM EDT

Kalaris Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-81.66	-69.17	-14.7	-15.49
Other Amortization	36.07	38.02	0.89	1.99
Asset Writedown & Restructuring Costs	-	-	-	0.16
Stock-Based Compensation	1.51	0.9	0.15	0.27
Other Operating Activities	11.23	11.71	0.62	-0.11
Change in Accounts Payable	3.05	-1.03	-0.4	1.83
Change in Other Net Operating Assets	-2.36	-1.1	-0.69	1.57
Operating Cash Flow	-32.16	-20.67	-14.13	-9.78
Short-Term Debt Issued	-	19.97	-	-
Long-Term Debt Issued	-	-	6	4.3
Total Debt Issued	17.47	19.97	6	4.3
Net Debt Issued (Repaid)	17.47	19.97	6	4.3
Issuance of Common Stock	0	0	-	0.01
Other Financing Activities	97.37	-2.42	-	-
Financing Cash Flow	114.85	19.14	14.24	12.78
Net Cash Flow	82.69	-1.53	0.11	3
Levered Free Cash Flow	-	-18.82	-9.43	-
Unlevered Free Cash Flow	-	-31.39	-9.34	-
Change in Working Capital	0.69	-2.13	-1.09	3.4

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q